12488411

Source:http://linkedlifedata.com/resource/pubmed/id/12488411

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0008838, umls-concept:C0010583, umls-concept:C0014582, umls-concept:C0015133, umls-concept:C0034656, umls-concept:C0040808, umls-concept:C0042679, umls-concept:C0282461, umls-concept:C0439234, umls-concept:C0684249, umls-concept:C1274040, umls-concept:C1282910, umls-concept:C1522577
pubmed:issue	24
pubmed:dateCreated	2002-12-18
pubmed:abstractText	To investigate whether chemotherapy with etoposide and cisplatin (EP) is superior to cyclophosphamide, epirubicin, and vincristine (CEV) in small-cell lung cancer (SCLC).
pubmed:commentsCorrections	http://linkedlifedata.com/resource/pubmed/commentcorrection/12488411-12488404
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/8309333
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Cisplatin, http://linkedlifedata.com/resource/pubmed/chemical/Cyclophosphamide, http://linkedlifedata.com/resource/pubmed/chemical/Epirubicin, http://linkedlifedata.com/resource/pubmed/chemical/Etoposide, http://linkedlifedata.com/resource/pubmed/chemical/Vincristine
pubmed:status	MEDLINE
pubmed:month	Dec
pubmed:issn	0732-183X
pubmed:author	pubmed-author:AamdalSteinarS, pubmed-author:AasebøUlfU, pubmed-author:BoyeNilsN, pubmed-author:BremnesRoy MRM, pubmed-author:DahleRagnarR, pubmed-author:HannisdalEinarE, pubmed-author:HatlevollReidulvR, pubmed-author:KaasaSteinS, pubmed-author:Norwegian Lung Cancer Study Group, pubmed-author:SkovlundEvaE, pubmed-author:SundstrømSteinS, pubmed-author:ViganderTorT, pubmed-author:VilsvikJanJ, pubmed-author:WangMariM
pubmed:issnType	Print
pubmed:day	15
pubmed:volume	20
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	4665-72
pubmed:dateRevised	2006-11-15
pubmed:meshHeading	pubmed-meshheading:12488411-Adult, pubmed-meshheading:12488411-Aged, pubmed-meshheading:12488411-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:12488411-Carcinoma, Small Cell, pubmed-meshheading:12488411-Cisplatin, pubmed-meshheading:12488411-Combined Modality Therapy, pubmed-meshheading:12488411-Cyclophosphamide, pubmed-meshheading:12488411-Epirubicin, pubmed-meshheading:12488411-Etoposide, pubmed-meshheading:12488411-Female, pubmed-meshheading:12488411-Follow-Up Studies, pubmed-meshheading:12488411-Humans, pubmed-meshheading:12488411-Lung Neoplasms, pubmed-meshheading:12488411-Male, pubmed-meshheading:12488411-Middle Aged, pubmed-meshheading:12488411-Quality of Life, pubmed-meshheading:12488411-Remission Induction, pubmed-meshheading:12488411-Survival Rate, pubmed-meshheading:12488411-Vincristine
pubmed:year	2002
pubmed:articleTitle	Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up.
pubmed:affiliation	Department of Oncology, University Hospital of Trondheim.
pubmed:publicationType	Journal Article, Clinical Trial, Comparative Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Clinical Trial, Phase III